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e read with great interest the recently published work of Bonello
t al. (1) regarding the clinical benefits of adjusting the loading
ose of clopidogrel prior to percutaneous coronary intervention
PCI) according to platelet reactivity index (PRI) of vasodilator-
timulated phosphoprotein assay. The study is brilliant to demon-
trate that low response to clopidogrel (defined as a PRI 50% in
asodilator-stimulated phosphoprotein assessment) increases the
isk of cardiovascular death and recurrent ischemia. Moreover,
epeated loading doses were successful in 86% of patients to
vercome high PRI that translated to better clinical outcomes.
owever, for the following reasons, implementation of these
ndings to clinical practice is unclear.
The study cohort comprised a mixed population of 46%
on–ST-segment elevation myocardial infarction (NSTEMI) and
4% nonacute coronary syndrome patients. Results of previous
tudies demonstrated that the net clinical benefit of intensifying
latelet inhibition during PCI is highly different between patients
f NSTEMI and stable angina. Likewise, neither clopidogrel
re-treatment nor administration of glycoprotein IIb/IIIa inhibi-
ors (GPI) reduced ischemic complications among troponin-
egative patients scheduled for elective PCI (2,3). Contrarily,
atients admitted with NSTEMI for primary PCI had signifi-
antly lower rates of major adverse cardiac events in cases of GPI
dministration and clopidogrel pre-treatment (4,5). Based on these
tudies, it would be essential to know whether the clinical
dvantages shown in the study were driven by the troponin-
ositive NSTEMI population or whether stable angina patients
lso profited from the repeated loading doses. In a clinical aspect,
here is no time limitation to optimize adenosine diphosphate-
nhibition among stable angina patients before PCI; however, those
dmitted with NSTEMI might be harmed from delays in reperfusion
hile waiting for loading doses to overcome the low response to
lopidogrel (6). As the latter patients might receive immediate GPI
herapy to have proper platelet inhibition, waiting days for repeated
oading doses does not seem the strategy of choice for them.
In conclusion, the landmark study of Bonello et al. (1) demon-
trated in a mixed patient population that optimizing clopidogrel
herapy according to a laboratory assay translates to significantly
etter short-term outcome after PCI. However, it is unclear how
hese results should affect current clinical practice. It seems highly
mportant to separate low-risk stable angina and NSTEMI pa-
ients to be able to draw clear clinical consequences for the best
ntiplatelet strategy before PCI.
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e thank Dr. Aradi and colleagues for their interest in our work
1). Our recently published trial is a pilot study that aimed to
emonstrate that platelet monitoring of response to thienopyri-
ines offers the promise of an improved outcome in patients
ndergoing percutaneous coronary intervention (PCI). Additional
tudies are needed to confirm those preliminary results and to
etermine which strategy of loading dose (LD) should be used.
hus, the present strategy of platelet reactivity (PR) monitoring
nd clopidogrel LD should not be used in clinical practice until
urther validation is reported.
As Dr. Aradi and colleagues highlighted, one potential limita-
ion of the present strategy of clopidogrel LD adjustment is the
ime required to tailor the LD to platelet monitoring. However, it
ust be noted that most patients in the vasodilator-stimulated
hosphoprotein-guided group had PCI after the second LD and
herefore underwent PCI within 48 h of admission. The optimal
elay between clopidogrel LD intakes should be defined by future
tudies to further reduce the time required for adjustment before
CI. Finally, a new P2Y12 adenosine diphosphate receptor that
nduces greater and faster PR inhibition may be particularly
nteresting in those subjects to limit the time required before PCI.
